Published in Pediatr Infect Dis J on March 01, 1988
Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults. BMJ (2002) 2.57
Cough management: a practical approach. Cough (2011) 1.23
Retracted Common colds. Causes, potential cures, and treatment. Can Fam Physician (1993) 1.15
Treatment of the common cold. BMJ (1998) 0.86
Treatment of congestion in upper respiratory diseases. Int J Gen Med (2010) 0.84
Older-generation antihistamines and cough due to upper airway cough syndrome (UACS): efficacy and mechanism. Lung (2007) 0.79
The Korean Cough Guideline: Recommendation and Summary Statement. Tuberc Respir Dis (Seoul) (2015) 0.79
Induction and relief of nasal congestion in ferrets infected with influenza virus. Int J Exp Pathol (1995) 0.78
Bronchitis (acute). BMJ Clin Evid (2011) 0.75
Cold comfort for the catarrhal child. Arch Dis Child (1990) 0.75
Bronchitis (acute). BMJ Clin Evid (2015) 0.75
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J (2001) 4.93
Influenza virus neuraminidase inhibitors. Lancet (2000) 4.89
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res (2002) 4.85
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis (2001) 3.69
Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother (1980) 3.60
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr (2000) 3.53
Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol (2003) 2.92
Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res (2001) 2.91
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med (1999) 2.76
Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol (2001) 2.58
Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother (1983) 2.53
Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA (1981) 2.50
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother (2001) 2.46
Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhalant allergens. Pediatrics (1993) 2.41
Hospital-based pneumococcal immunization. Epidemiologic rationale from the Shenandoah study. JAMA (1990) 2.14
Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microbiol (1997) 2.09
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis (1999) 2.03
Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother (1981) 1.99
Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am J Infect Control (1989) 1.98
Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol (1999) 1.98
Chronic traumatic thoracic aneurysm. Influence of operative treatment on natural history: an analysis of reported cases, 1950-1980. J Thorac Cardiovasc Surg (1982) 1.95
Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics (1998) 1.94
Etiology of acute conjunctivitis in children. J Pediatr (1981) 1.92
Multiple use of disposable insulin syringe-needle units. JAMA (1980) 1.89
Relation between surgical volume and incidence of postoperative wound infection. N Engl J Med (1981) 1.87
Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis (1998) 1.85
Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis (1995) 1.84
Picornavirus infections: a primer for the practitioner. Arch Fam Med (2000) 1.80
Clinical effectiveness of influenza vaccination in Manitoba. JAMA (1993) 1.78
Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. J Clin Microbiol (1997) 1.76
Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am (1987) 1.73
Comparison of the Immulok cultureset kit and virus isolation for detection of herpes simplex virus in clinical specimens. J Clin Microbiol (1983) 1.64
Postinfarction ventricular septal rupture: the importance of location of infarction and right ventricular function in determining survival. Circulation (1986) 1.63
Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab (1987) 1.58
Rapid diagnosis of influenza A and B by 24-h fluorescent focus assays. J Clin Microbiol (1988) 1.57
Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med (1986) 1.56
Health perceptions of primary care patients and the influence on health care utilization. Med Care (1989) 1.53
Improving preventive care at a medical clinic: how can the patient help? Am J Prev Med (1990) 1.50
Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother (1999) 1.49
Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol (1989) 1.48
Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation (1983) 1.46
Epidemiologic evidence for Lancefield group C beta-hemolytic streptococci as a cause of exudative pharyngitis in college students. J Clin Microbiol (1997) 1.45
Comparison of outcome of asymptomatic to symptomatic patients older than 20 years of age with valvular aortic stenosis. Am J Cardiol (1988) 1.43
In vitro activity of zinc salts against human rhinoviruses. Antimicrob Agents Chemother (1987) 1.40
Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis (2000) 1.40
Detection of human rhinovirus RNA in nasal washings by PCR. Mol Cell Probes (1993) 1.39
Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax (1989) 1.36
Contemporary aspects of discrete peak-detection algorithms. I. The paradigm of the luteinizing hormone pulse signal in men. Endocr Rev (1988) 1.33
Chemotherapy of rhinovirus colds. Antimicrob Agents Chemother (1988) 1.30
Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness. J Infect Dis (1983) 1.30
Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother (1985) 1.29
Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA (1999) 1.28
Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother (1980) 1.28
Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis (1991) 1.27
Activity of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro. Antimicrob Agents Chemother (1982) 1.27
Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds. Antimicrob Agents Chemother (1988) 1.25
Enterovirus meningitis in adults. Clin Infect Dis (1998) 1.25
Urinary tract etiology of bloodstream infections in hospitalized patients. J Infect Dis (1983) 1.24
Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man. Lancet (1983) 1.23
Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother (1982) 1.22
Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J Infect Dis (1995) 1.21
Comparative susceptibilities of human embryonic fibroblasts and HeLa cells for isolation of human rhinoviruses. J Clin Microbiol (1996) 1.19
Alterations of the eustachian tube, middle ear, and nose in rhinovirus infection. Arch Otolaryngol Head Neck Surg (1989) 1.18
In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res (2000) 1.18
Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control. J Infect Dis (1993) 1.17
Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother (1986) 1.13
Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA (1988) 1.13
New approaches to influenza chemotherapy. Neuraminidase inhibitors. Drugs (1998) 1.13
Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antivir Ther (1999) 1.12
Acute respiratory viral infections in ambulatory children of urban northeast Brazil. J Infect Dis (1991) 1.12
Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother (1984) 1.11
T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations. Kidney Int (1987) 1.11
Anti-interferon antibody increases rhinovirus isolation rates from nasal wash specimens containing interferon-alpha 2. Antiviral Res (1983) 1.10
Rhinoviruses: important respiratory pathogens. Ann Med (1998) 1.09
Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. J Infect Dis (1980) 1.08
In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1. Antimicrob Agents Chemother (1992) 1.07
A comprehensive analysis of myocardial infarction due to left circumflex artery occlusion: comparison with infarction due to right coronary artery and left anterior descending artery occlusion. J Am Coll Cardiol (1988) 1.06
Acute febrile cerebrovasculitis: a syndrome of unknown, perhaps rickettsial, cause. Ann Intern Med (1986) 1.05
Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. J Infect Dis (1984) 1.04
Increased interleukin-6 levels in nasal lavage samples following experimental influenza A virus infection. Clin Diagn Lab Immunol (1998) 1.04
Physiologic abnormalities in the paranasal sinuses during experimental rhinovirus colds. J Allergy Clin Immunol (1992) 1.04
Clinical features of patients with acute respiratory illness and rhinovirus in their bronchoalveolar lavages. J Clin Virol (2001) 1.03
Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2. J Infect Dis (1983) 1.03
Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med (2000) 1.03
Acute non-Q wave myocardial infarction associated with early ST segment elevation: evidence for spontaneous coronary reperfusion and implications for thrombolytic trials. J Am Coll Cardiol (1987) 1.03
Acceptance of hepatitis B vaccine by medical and surgical residents. J Gen Intern Med (1988) 1.03
Catheter-associated bacteriuria. Failure to reduce attack rates using periodic instillations of a disinfectant into urinary drainage systems. JAMA (1984) 1.01
Immunoblot studies to analyze antibody to the Rickettsia typhi group antigen in sera from patients with acute febrile cerebrovasculitis. J Clin Microbiol (1991) 1.00
Prognostic factors in head and neck melanoma. Effect of lesion location. Cancer (1988) 1.00
Organ-specific autoantibodies in children with common endocrine diseases. J Pediatr (1982) 1.00
Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections. Antiviral Res (1985) 0.99
Can success in the surgical residency be predicted from preresidency evaluation? Ann Surg (1985) 0.98
Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis (1998) 0.98
A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis (1990) 0.97
Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. J Infect Dis (1997) 0.97
The prevalence and clinical significance of residual myocardial ischemia 2 weeks after uncomplicated non-Q wave infarction: a prospective natural history study. Circulation (1986) 0.97